Cargando…
Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India
Lymphatic filariasis (LF) is a vector-borne neglected tropical disease, causing permanent disability. The disease is debilitating and widespread, leading to tremendous productivity and economic loss. The Government of India (GOI) prioritized the elimination of LF through the annual mass drug adminis...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707683/ https://www.ncbi.nlm.nih.gov/pubmed/36124509 http://dx.doi.org/10.4103/ijmr.ijmr_171_22 |
_version_ | 1784840754129010688 |
---|---|
author | Sabesan, S. Krishnamoorthy, K. Hoti, S.L. Subramanian, S. Srividya, A. Roy, Nupur Jain, Tanu Kumar, Ashwani Rahi, Manju |
author_facet | Sabesan, S. Krishnamoorthy, K. Hoti, S.L. Subramanian, S. Srividya, A. Roy, Nupur Jain, Tanu Kumar, Ashwani Rahi, Manju |
author_sort | Sabesan, S. |
collection | PubMed |
description | Lymphatic filariasis (LF) is a vector-borne neglected tropical disease, causing permanent disability. The disease is debilitating and widespread, leading to tremendous productivity and economic loss. The Government of India (GOI) prioritized the elimination of LF through the annual mass drug administration (MDA) programme in 2004 and continued with a single dose of diethylcarbamazine citrate (DEC), 6 mg/kg of body weight, plus albendazole annually over a period of 5-6 years. The GOI had set the target to achieve LF elimination by 2015 and now by 2030. The progress so far has been suboptimal. Much remains to be done as about 84 per cent of the total 328 endemic districts are still under MDA. The major challenge in implementing MDA is poor compliance. It is necessary to have a feasible alternative strategy addressing the above challenge to achieve the desired goal of LF elimination. At this juncture, a well-researched approach, i.e. the use of DEC-fortified salt, also advocated by the World Health Organization, as a unique form of MDA, is proposed. As per this strategy, a low dose of DEC (0.2% w/w) is added to the cooking salt at the manufacturing facility of iodized salt and consumed by the LF-endemic communities for about two years. Many examples of successful use of this strategy for LF elimination in small- and large-scale trials have been documented in India and several other endemic countries in the world. Implementing DEC–iodine-fortified salt is a safe, less expensive, more efficient and prompt approach for achieving the elimination of LF in India. Adverse effects are none or minor and self-limiting. The DEC-fortified salt strategy can easily piggyback on the existing countrywide deployment of iodized salt under the National Iodine Deficiency Disorders Control Programme (NIDDCP), which has achieved a great success in reducing iodine-deficiency disorders such as hypothyroidism. This existing robust programme can be leveraged to launch DEC-fortified salt for the community. If implemented appropriately, this strategy will ensure the complete cessation of LF transmission within two years from its introduction. If the said strategy is implemented in 2022, it is expected that India will be able to achieve the LF elimination by 2024, much before the global target of 2030. |
format | Online Article Text |
id | pubmed-9707683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-97076832022-11-30 Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India Sabesan, S. Krishnamoorthy, K. Hoti, S.L. Subramanian, S. Srividya, A. Roy, Nupur Jain, Tanu Kumar, Ashwani Rahi, Manju Indian J Med Res Policy Guidelines Lymphatic filariasis (LF) is a vector-borne neglected tropical disease, causing permanent disability. The disease is debilitating and widespread, leading to tremendous productivity and economic loss. The Government of India (GOI) prioritized the elimination of LF through the annual mass drug administration (MDA) programme in 2004 and continued with a single dose of diethylcarbamazine citrate (DEC), 6 mg/kg of body weight, plus albendazole annually over a period of 5-6 years. The GOI had set the target to achieve LF elimination by 2015 and now by 2030. The progress so far has been suboptimal. Much remains to be done as about 84 per cent of the total 328 endemic districts are still under MDA. The major challenge in implementing MDA is poor compliance. It is necessary to have a feasible alternative strategy addressing the above challenge to achieve the desired goal of LF elimination. At this juncture, a well-researched approach, i.e. the use of DEC-fortified salt, also advocated by the World Health Organization, as a unique form of MDA, is proposed. As per this strategy, a low dose of DEC (0.2% w/w) is added to the cooking salt at the manufacturing facility of iodized salt and consumed by the LF-endemic communities for about two years. Many examples of successful use of this strategy for LF elimination in small- and large-scale trials have been documented in India and several other endemic countries in the world. Implementing DEC–iodine-fortified salt is a safe, less expensive, more efficient and prompt approach for achieving the elimination of LF in India. Adverse effects are none or minor and self-limiting. The DEC-fortified salt strategy can easily piggyback on the existing countrywide deployment of iodized salt under the National Iodine Deficiency Disorders Control Programme (NIDDCP), which has achieved a great success in reducing iodine-deficiency disorders such as hypothyroidism. This existing robust programme can be leveraged to launch DEC-fortified salt for the community. If implemented appropriately, this strategy will ensure the complete cessation of LF transmission within two years from its introduction. If the said strategy is implemented in 2022, it is expected that India will be able to achieve the LF elimination by 2024, much before the global target of 2030. Wolters Kluwer - Medknow 2022 /pmc/articles/PMC9707683/ /pubmed/36124509 http://dx.doi.org/10.4103/ijmr.ijmr_171_22 Text en Copyright: © 2022 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Policy Guidelines Sabesan, S. Krishnamoorthy, K. Hoti, S.L. Subramanian, S. Srividya, A. Roy, Nupur Jain, Tanu Kumar, Ashwani Rahi, Manju Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India |
title | Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India |
title_full | Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India |
title_fullStr | Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India |
title_full_unstemmed | Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India |
title_short | Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India |
title_sort | diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in india |
topic | Policy Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707683/ https://www.ncbi.nlm.nih.gov/pubmed/36124509 http://dx.doi.org/10.4103/ijmr.ijmr_171_22 |
work_keys_str_mv | AT sabesans diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT krishnamoorthyk diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT hotisl diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT subramanians diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT srividyaa diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT roynupur diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT jaintanu diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT kumarashwani diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia AT rahimanju diethylcarbamazinecitratefortifiedsaltforlymphaticfilariasiseliminationinindia |